Droxidopa
- Generic Name
- Droxidopa
- Brand Names
- Northera
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO5
- CAS Number
- 23651-95-8
- Unique Ingredient Identifier
- J7A92W69L7
- Background
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopa...
- Indication
For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainti...
- Associated Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Associated Therapies
- -
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 225
- Registration Number
- NCT01176240
- Locations
- 🇺🇸
Northwest Neuro Specialists P.L.L.C., Tucson, Arizona, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Eastern Connecticut Neurology Specialists, Manchester, Connecticut, United States
Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa
- Conditions
- Interventions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT01149629
- Locations
- 🇺🇸
Cetero Research, Fargo, North Dakota, United States
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 350
- Registration Number
- NCT01132326
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT00977171
- Locations
- 🇺🇸
7421 Carmel Executive Park Drive, Ste. 320, Charlotte, North Carolina, United States
Long Term Treatment With L-DOPS
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Vanderbilt University
- Registration Number
- NCT00889135
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 263
- Registration Number
- NCT00782340
- Locations
- 🇨🇦
Movment Disorder Clinic Deer lodge Centre, Winnipeg, Manitoba, Canada
🇺🇸Mayo Clinic-Arizona, Scottsdale, Arizona, United States
🇨🇦IRCM, Montreal, Quebec, Canada
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 103
- Registration Number
- NCT00738062
- Locations
- 🇺🇸
Saint Mary of Nazareth Hospital Center, Chicago, Illinois, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT00657046
- Locations
- 🇺🇸
Rogue Valley Dialysis, Medford, Oregon, United States
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Chelsea Therapeutics
- Target Recruit Count
- 181
- Registration Number
- NCT00633880
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸The Parkinson's Institute, Sunnyvale, California, United States
🇺🇸Parkinson's Disease & Movment Disorder Center, Boca Raton, Florida, United States
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
- Conditions
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2014-07-17
- Target Recruit Count
- 14
- Registration Number
- NCT00547911
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.